67 patents
Utility
Methods of Intravenous Administration of Glyburide
28 Dec 23
The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 μg/hr and about 300 μg/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.
Sven Martin JACOBSON
Filed: 20 Jan 23
Utility
Compositions and Methods for Treating Macular Dystrophy
18 May 23
The disclosure provides composition comprising a nucleic acid sequence comprising (a) a sequence encoding a vitelliform macular dystrophy-2 (VMD2) promoter, and (b) a sequence encoding a Bestrophin-1 (BEST1) protein as well as the use of these compositions for the treatment of macular dystrophy in a subject comprising administration of the composition to an eye of a subject via a subretinal or a suprachoroidal route.
Robert E. Maclaren, Cristina Martinez-Fernandez de la Camara, Gregory S. Robinson
Filed: 15 Sep 22
Utility
Methods of intravenous administration of glyburide
24 Jan 23
The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 μg/hr and about 300 μg/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours.
Sven Martin Jacobson
Filed: 24 Sep 20
Utility
Process for Preparing Alpha-carboxamide Pyrrolidine Derivatives
10 Nov 22
The disclosure relates to novel processes for preparing α-carboxamide pyrrolidine derivatives, in particular (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide, and to novel intermediates for use in said process along with processes for preparing said intermediates.
Weirong Chen, Vinny Couming, Erwin Irdam, William F. Kiesman, Daw-long A. Kwok, Tamera L. Mack, Suzanne M. Opalka, Daniel B. Patience, Donald G. Walker, Wenli Liang
Filed: 24 Nov 21
Utility
Low-sorbing Glyburide Formulation and Methods
8 Sep 22
Methods and formulations for minimizing or avoiding the sorption of glyburide to surfaces of delivery tubing, filters, bags, and other containers and materials, thereby storing and delivering a more stable product, delivering a predictable and accurate dose of glyburide, while minimizing impurities, avoiding drug waste, reducing cost, and significantly reducing the amount of dosing solution that must be infused into the patient.
Kenny K. TRAN, Deirdre LOWE, Rupa Rishikesh SAWANT, Haihong CHEN, Yiqing LIN
Filed: 4 Mar 22
Utility
Methods for Treating Alzheimer's Disease
8 Sep 22
Provided are methods for treating Alzheimer's disease in a human subject in need thereof when the subject develops an Amyloid Related Imaging Abnormality (ARIA) during a treatment regimen comprising administration of multiple doses of an anti-beta-amyloid antibody (e.g., BIIB037) to the subject.
Brendon Phillip Boot, Jeffrey Joseph Sevigny, Leslie Lugene Williams
Filed: 25 Feb 22
Utility
Method for Treating Subjects Suffering from Central Nervous System Contusions
21 Jul 22
Methods of inhibiting expansion of cerebral contusion, inhibiting secondary hemorrhage and capillary fragmentation in the brain, reducing pericontusional edema and hemorrhage size in the brain, decreasing water content in a CNS tissue, inhibiting disruption of the blood-brain barrier, inhibiting CNS contusion progression and improving post-contusion motor function, inhibiting microvascular impairment caused by endothelial cell swelling and fragmentation, inhibiting extravasation of blood into the brain parenchyma of a subject, inhibiting endothelial cell breakdown in a brain tissue, inhibiting extravasation of endovascular fluids into the brain's interstitium, decreasing vasogenic edema as measured by T2 flair magnetic resonance imaging, and decreasing matrix metalloprotease concentration in a CNS tissue, by administering a SUR1-TRPM4 channel inhibitor alone or in combination with one or more drugs or agents.
Jacob SB ELKINS
Filed: 30 Apr 20
Utility
Pharmaceutical Composition Containing Dimethyl Fumarate for Administration at a Low Daily Dose
2 Jun 22
The present invention relates to pharmaceutical compositions containing dimethyl fumarate (DMF), More specifically, the present invention relates to a pharmaceutical composition for oral use in treating hyperproliferative, inflammatory or autoimmune disorders by administering a low daily dosage in the range of 410 mg±5% or 400 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet.
Christin Galetzka, Chris Rundfeldt, Roland Rupp, Peder M. Andersen
Filed: 16 Feb 22
Utility
Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins
24 May 22
The present disclosure provides methods of assaying for antibody-dependent cell-mediated phagocytosis (ADCP).
Carl Co, Allyson Masci, Svetlana Bergelson
Filed: 14 Mar 17
Utility
Methods of Treating Injuries or Conditions Related to CNS Edema
28 Apr 22
The present technology is related to reducing or treating neurological swelling and related conditions with SUR1-TRPM4 channel inhibitors.
Sven Martin JACOBSON
Filed: 29 Sep 21
Utility
Methods of medical treatment with SUR1-TRPM4 channel inhibitors
19 Apr 22
A method of treating or preventing adverse outcomes associated with tissue plasminogen activator (tPA) administration, cerebral edema-related side effects, cerebral edema associated with radiation therapy, or migraine headaches by administering an effective amount of a SUR1-TRPM4 channel inhibitor, such as glyburide, and optionally the co-administration of a second therapeutically active agent, to a subject in need thereof.
Sven Jacobson, Thomas Macallister
Filed: 28 Jul 17
Utility
Diagnostic Method
31 Mar 22
The invention relates to a method of diagnosing a paroxysmal pain disorder, such as trigeminal neuralgia, in a human subject and also provides a method of identifying patients most likely to respond to therapy and to kits for use in said methods.
Valerie Morisset
Filed: 17 May 21
Utility
Methods of Medical Treatment with SUR1-TRPM4 Channel Inhibitors
24 Mar 22
A method of treating or preventing adverse outcomes associated with tissue plasminogen activator (tPA) administration, cerebral edema-related side effects, cerebral edema associated with radiation therapy, or migraine headaches by administering an effective amount of a SUR1-TRPM4 channel inhibitor, such as glyburide, and optionally the co-administration of a second therapeutically active agent, to a subject in need thereof.
Sven JACOBSON, Thomas MACALLISTER
Filed: 6 Dec 21
Utility
Pharmaceutical Formulation Comprising One or More Fumaric Acid Esters In an Erosion Matrix
17 Mar 22
A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).
Henrik Nilsson, Roland Rupp
Filed: 12 Oct 21
Utility
Process for Preparing Spiro Derivatives
3 Feb 22
The invention relates to a novel process for preparing spiro derivatives, in particular 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one, and to novel intermediates for use in said process along with processes for preparing said intermediates.
Gerard M. Giblin, David T. MacPherson, Osama Suleiman, Michael Williams, David R. Witty, Thierry Bonnaud, Richard Edwards
Filed: 15 Oct 21
Utility
Controlled release pharmaceutical compositions comprising a fumaric acid ester
25 Jan 22
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s).
Henrik Nilsson, Bernd W. Mueller
Filed: 20 Dec 18
Utility
Process for preparing alpha-carboxamide pyrrolidine derivatives
7 Dec 21
The invention relates to a novel process for preparing a-carboxamide pyrrolidine derivatives, in particular (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide, and to novel intermediates for use in said process along with processes for preparing said intermediates.
Weirong Chen, Vinny Couming, Erwin Irdam, William F. Kiesman, Daw-Long A. Kwok, Tamera L. Mack, Suzanne M. Opalka, Daniel B. Patience, Donald G. Walker, Wenli Liang
Filed: 5 Oct 18
Utility
Compositions and Methods for Manufacturing Gene Therapy Vectors
18 Nov 21
Disclosed are methods for the production and/or purification of a recombinant AAV (rAAV) particle from a mammalian host cell culture.
Julian Hanak, Richard Truran
Filed: 23 Sep 19
Utility
Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
16 Nov 21
A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).
Henrik Nilsson, Roland Rupp
Filed: 28 Nov 18
Utility
Compositions and Methods for Treating Retinitis Pigmentosa
11 Nov 21
The disclosure relates to compositions and methods for the treatment of Retinitis Pigmentosa through the administration of a rAAV vector comprising an RPGRORF15 sequence
Gregory S. Robinson, Tuyen Ong
Filed: 23 Sep 19